drugset / Trial / NCT01743807
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Phase 1
Terminated
4 enrolled
Therapeutic Advances in Childhood Leukemia Consortium
SBI Biotech Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I trial of an investigational drug called GNKG168 in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) who are in morphologic remission but are positive for Minimum Residual Disease (MRD).
Timeline
- Start
- 2014-03-26
- Primary completion
- 2014-07-28
- Completion
- 2014-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GNKG168 | Oligonucleotide (other) | 0.15 mg/kg | Intravenous |
| Subject | GNKG168 | Oligonucleotide (other) | 0.25 mg/kg | Intravenous |
| Subject | GNKG168 | Oligonucleotide (other) | 0.75 mg/kg | Intravenous |
| Subject | GNKG168 | Oligonucleotide (other) | 1.5 mg/kg | Intravenous |